tradingkey.logo

Organon & Co

OGN
7.185USD
+0.095+1.34%
收盘 12/26, 16:00美东报价延迟15分钟
1.87B总市值
3.72市盈率 TTM

Organon & Co

7.185
+0.095+1.34%

关于 Organon & Co 公司

Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.

Organon & Co简介

公司代码OGN
公司名称Organon & Co
上市日期May 14, 2021
CEOMorrissey (Joseph T)
员工数量10000
证券类型Ordinary Share
年结日May 14
公司地址30 Hudson Street
城市JERSEY CITY
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家United States of America
邮编07302
电话15514306000
网址https://www.organon.com/
公司代码OGN
上市日期May 14, 2021
CEOMorrissey (Joseph T)

Organon & Co公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
144.48K
+8.57%
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
71.89K
+18.29%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
59.92K
+10.11%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
52.85K
+17.96%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
41.33K
+26.65%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Independent Director
Independent Director
2.00
--
Ms. Ramona A. Sequeira
Ms. Ramona A. Sequeira
Independent Director
Independent Director
--
--
Mr. Robert A. (Bob) Essner
Mr. Robert A. (Bob) Essner
Lead Independent Director
Lead Independent Director
--
--
Ms. Grace M. Puma Whiteford
Ms. Grace M. Puma Whiteford
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
144.48K
+8.57%
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
71.89K
+18.29%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
59.92K
+10.11%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
52.85K
+17.96%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
41.33K
+26.65%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Women’s Health
462.00M
28.98%
Cardiovascular
283.00M
17.75%
Non-Opioid Pain, Bone and Dermatology
250.00M
15.68%
Respiratory
220.00M
13.80%
Other
206.00M
12.92%
Biosimilars
173.00M
10.85%
地区USD
名称
营收
占比
Europe and Canada
419.00M
26.29%
United States
414.00M
25.97%
Latin America, Middle East, Russia and Africa
285.00M
17.88%
Asia Pacific and Japan
250.00M
15.68%
China
204.00M
12.80%
Other
22.00M
1.38%
业务
地区
业务USD
名称
营收
占比
Women’s Health
462.00M
28.98%
Cardiovascular
283.00M
17.75%
Non-Opioid Pain, Bone and Dermatology
250.00M
15.68%
Respiratory
220.00M
13.80%
Other
206.00M
12.92%
Biosimilars
173.00M
10.85%

股东统计

更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
13.76%
BlackRock Institutional Trust Company, N.A.
10.68%
MFS Investment Management
3.63%
State Street Investment Management (US)
3.59%
LSV Asset Management
3.01%
其他
65.33%
持股股东
持股股东
占比
The Vanguard Group, Inc.
13.76%
BlackRock Institutional Trust Company, N.A.
10.68%
MFS Investment Management
3.63%
State Street Investment Management (US)
3.59%
LSV Asset Management
3.01%
其他
65.33%
股东类型
持股股东
占比
Investment Advisor
47.62%
Investment Advisor/Hedge Fund
20.77%
Hedge Fund
4.75%
Pension Fund
2.56%
Research Firm
2.06%
Bank and Trust
0.92%
Sovereign Wealth Fund
0.86%
Individual Investor
0.36%
Venture Capital
0.04%
其他
20.06%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
1485
219.88M
84.58%
-37.41M
2025Q2
1527
205.34M
78.98%
-50.49M
2025Q1
1611
213.21M
82.04%
-52.34M
2024Q4
1647
218.39M
84.67%
-40.43M
2024Q3
1625
211.80M
82.26%
-47.57M
2024Q2
1676
208.67M
81.14%
-51.47M
2024Q1
1700
205.29M
80.30%
-45.21M
2023Q4
1767
202.90M
79.38%
-24.07M
2023Q3
1835
205.61M
80.45%
-25.35M
2023Q2
2016
205.94M
80.75%
-21.55M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
32.15M
12.37%
+2.54M
+8.57%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
28.28M
10.88%
-627.34K
-2.17%
Jun 30, 2025
MFS Investment Management
10.11M
3.89%
-469.39K
-4.44%
Jun 30, 2025
State Street Investment Management (US)
9.52M
3.66%
+540.48K
+6.02%
Jun 30, 2025
LSV Asset Management
7.99M
3.07%
+8.69K
+0.11%
Jun 30, 2025
Geode Capital Management, L.L.C.
4.40M
1.69%
-121.50K
-2.69%
Jun 30, 2025
Millennium Management LLC
9.09M
3.5%
+8.11M
+829.74%
Jun 30, 2025
AQR Capital Management, LLC
3.25M
1.25%
+1.88M
+136.10%
Jun 30, 2025
Gotham Asset Management, LLC
2.71M
1.04%
+1.31M
+93.22%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
4.63M
1.78%
+459.24K
+11.02%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
State Street SPDR S&P Pharmaceuticals ETF
1.72%
Alger Russell Innovation ETF
1.39%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.22%
First Trust Health Care Alphadex Fund
1.1%
Invesco S&P SmallCap Health Care ETF
1.07%
Brandes US Small-Mid Cap Value ETF
1.05%
iShares U.S. Pharmaceuticals ETF
0.65%
Lattice Hartford Multifactor Small Cap ETF
0.5%
WisdomTree U.S. SmallCap Dividend Fund
0.5%
Royce Quant Small-Cap Quality Value ETF
0.45%
查看更多
State Street SPDR S&P Pharmaceuticals ETF
占比1.72%
Alger Russell Innovation ETF
占比1.39%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比1.22%
First Trust Health Care Alphadex Fund
占比1.1%
Invesco S&P SmallCap Health Care ETF
占比1.07%
Brandes US Small-Mid Cap Value ETF
占比1.05%
iShares U.S. Pharmaceuticals ETF
占比0.65%
Lattice Hartford Multifactor Small Cap ETF
占比0.5%
WisdomTree U.S. SmallCap Dividend Fund
占比0.5%
Royce Quant Small-Cap Quality Value ETF
占比0.45%

分红派息

近5年累计派现 1.03B 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Nov 10, 2025
OGN.NB Final Cash Dividend of gross USD 0.02 paid on Dec 11, 2025 going ex on Nov 20, 2025
Nov 20, 2025
Dec 11, 2025
Nov 20, 2025
Aug 05, 2025
OGN.NB Interim Cash Dividend of gross USD 0.02 paid on Sep 11, 2025 going ex on Aug 15, 2025
Aug 15, 2025
Sep 11, 2025
Aug 15, 2025
May 01, 2025
OGN.NB Interim Cash Dividend of gross USD 0.02 paid on Jun 12, 2025 going ex on May 12, 2025
May 12, 2025
Jun 12, 2025
May 12, 2025
Feb 13, 2025
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 13, 2025 going ex on Feb 24, 2025
Feb 24, 2025
Mar 13, 2025
Feb 24, 2025
Oct 31, 2024
OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 12, 2024 going ex on Nov 12, 2024
Nov 12, 2024
Dec 12, 2024
Nov 12, 2024
Aug 06, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 12, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Sep 12, 2024
Aug 16, 2024
May 02, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Jun 13, 2024 going ex on May 10, 2024
May 13, 2024
Jun 13, 2024
May 10, 2024
Feb 15, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 14, 2024 going ex on Feb 23, 2024
Feb 26, 2024
Mar 14, 2024
Feb 23, 2024
Nov 02, 2023
OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 14, 2023 going ex on Nov 10, 2023
Nov 13, 2023
Dec 14, 2023
Nov 10, 2023
Aug 08, 2023
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 14, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 14, 2023
Aug 17, 2023
查看更多

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Organon & Co的前五大股东是谁?

Organon & Co 的前五大股东如下:
The Vanguard Group, Inc.持有股份:32.15M,占总股份比例:12.37%。
BlackRock Institutional Trust Company, N.A.持有股份:28.28M,占总股份比例:10.88%。
MFS Investment Management持有股份:10.11M,占总股份比例:3.89%。
State Street Investment Management (US)持有股份:9.52M,占总股份比例:3.66%。
LSV Asset Management持有股份:7.99M,占总股份比例:3.07%。

Organon & Co的前三大股东类型是什么?

Organon & Co 的前三大股东类型分别是:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
MFS Investment Management

有多少机构持有Organon & Co(OGN)的股份?

截至2025Q3,共有1485家机构持有Organon & Co的股份,合计持有的股份价值约为219.88M,占公司总股份的84.58%。与2025Q2相比,机构持股有所增加,增幅为5.59%。

哪个业务部门对Organon & Co的收入贡献最大?

在FY2025Q2,Women’s Health业务部门对Organon & Co的收入贡献最大,创收462.00M,占总收入的28.98%。
KeyAI